Role Perceptions of EFL Learners in Human-GenAI Collaborative Revision: A Q-Methodological Study
International Journal of English Literature and Social Sciences · 2026 · 11 (6) · 191-197
DOI: 10.22161/ijels.116.26 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of English Literature and Social Sciences, 2026. Verfasst von Yufei Wan.
Abstract (Originalsprache)
Generative artificial intelligence (GenAI) is increasingly being used as a cognitive partner rather than merely an auxiliary writing tool. Previous research has largely examined learners’ evaluations of GenAI functions and perceived risks, whereas role perceptions in human-GenAI collaborative writing revision have received limited systematic attention. Using Q methodology, this study identifies two role-perception types among EFL learners: the Open Collaborative Type and the Prudent Autonomous Type. Both groups value integrating GenAI suggestions with their own ideas and reject delegating all revision decisions to GenAI. However, they differ in their views of feedback evaluation and uptake, revision-goal setting, and control over the revision process. These findings offer evidence on how learners understand cognitive responsibilities in GenAI-supported L2 writing revision.
Zitieren
APA
Wan, Y. (2026). Role Perceptions of EFL Learners in Human-GenAI Collaborative Revision: A Q-Methodological Study. International Journal of English Literature and Social Sciences, 11(6), 191-197. https://doi.org/10.22161/ijels.116.26
Vancouver
Wan Y. Role Perceptions of EFL Learners in Human-GenAI Collaborative Revision: A Q-Methodological Study. International Journal of English Literature and Social Sciences. 2026;11(6):191-197. doi:10.22161/ijels.116.26
BibTeX
@article{Wan2026,
author = {Wan, Yufei},
title = {Role Perceptions of EFL Learners in Human-GenAI Collaborative Revision: A Q-Methodological Study},
journal = {International Journal of English Literature and Social Sciences},
year = {2026},
volume = {11},
number = {6},
pages = {191--197},
doi = {10.22161/ijels.116.26}
}
EUVIMED